Expert Interview
A look at the Phase 2b REZILIENT1 trial evaluating Taiho Pharmaceutical's zipalertinib in patients with EGFR Exon 20 insertion mutation–positive non-small cell lung cancer.
Ticker(s): TAIHO PHARMACEUTICAL, CGEMInstitution: University of Colorado
- Chair in Cancer Research, Distinguished Professor, Medicine-Medical Oncology, & Founding Director of the University of Colorado Cancer Center.
- Past president of the International Association for the Study of Lung Cancer (IASLC) and the American Society of Clinical Oncology (ASCO); served as chairman of the FDA Oncology Drug Advisory Committee.
- Currently managing 4 patients with mesothelioma.
- Research focuses on novel molecular therapies and immunotherapies for lung cancer and other thoracic cancers.
How do you interpret the efficacy outcomes from the REZILIENT1 trial of zipalertinib, particularly in the context of other approved therapies for EGFR Exon 20 insertion NSCLC, such as amivantamab or mobocertinib?
Added By: sara_adminWere there any safety or tolerability findings in REZILIENT1 that you found especially notable or potentially practice-changing for treating this difficult-to-target patient subgroup?
Added By: sara_adminDo you think zipalertinib could become a preferred second-line option in this population, or will its future depend more on biomarker refinement or sequencing strategies?
Added By: sara_adminAre You Interested In These Questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
